Substance / Medication

Eprosartan mesylate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Research Evidence

Published studies and systematic reviews

Sort:
Eprosartan mesylate effectively reduces systolic and diastolic blood pressure in a Canadian primary care setting.
Conter Howard S, McKay Donald W, Reiz Ruby J Shanlin · Can J Cardiol · 2004
PMID: 16807617Observational
The angiotensin receptor blocker eprosartan mesylate reduces pulse pressure in isolated systolic hypertension.
Teitelbaum Ivor, Chilvers Martyn, Reiz Ruby J Shanlin · Can J Cardiol · 2004
PMID: 16807618Observational
Formulation and characterization of eprosartan mesylate and β-cyclodextrin inclusion complex prepared by microwave technology.
Ahad Abdul, Bin Jardan Yousef A, Hassan Mohd Zaheen et al. · Drug Deliv · 2022
PMID: 35549506OtherFull text (PMC)
Self-microemulsifying Drug Delivery System for Solubility and Bioavailability Enhancement of Eprosartan Mesylate: Preparation,, andEvaluation.
Patil Mukesh Subhash, Shirkhedkar Atul Arunrao · Pharm Nanotechnol · 2023
PMID: 36111774Preclinical
Enhanced dissolution/caco-2 permeability, pharmacokinetic and pharmacodynamic performance of re-dispersible eprosartan mesylate nanopowder.
Shekhawat Prachi, Bagul Milind, Edwankar Diptee et al. · Eur J Pharm Sci · 2019
PMID: 30797937Preclinical
Formulation and characterization of Phospholipon 90 G and tween 80 based transfersomes for transdermal delivery of eprosartan mesylate.
Ahad Abdul, Al-Saleh Abdulmohsen A, Al-Mohizea Abdullah M et al. · Pharm Dev Technol · 2018
PMID: 28504046Preclinical
Eprosartan mesylate loaded bilosomes as potential nano-carriers against diabetic nephropathy in streptozotocin-induced diabetic rats.
Ahad Abdul, Raish Mohammad, Ahmad Ajaz et al. · Eur J Pharm Sci · 2018
PMID: 29030177Preclinical
Pharmacodynamic study of eprosartan mesylate-loaded transfersomes Carbopolgel under Dermarolleron rats with methyl prednisolone acetate-induced hypertension.
Ahad Abdul, Al-Saleh Abdulmohsen A, Al-Mohizea Abdullah M et al. · Biomed Pharmacother · 2017
PMID: 28237913Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Eprosartan mesilate (substance)
SNOMED CT
129488003
UMLS CUI
C0772203

Clinical Data

This intervention maps to 10 entities in the Ltrl knowledge graph.

3
Conditions
4
Biomarkers
2
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.